These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 31092408)
1. Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1. Murai J; Pommier Y Cancer Res; 2019 May; 79(10):2460-2461. PubMed ID: 31092408 [TBL] [Abstract][Full Text] [Related]
2. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair. Wang F; Zhu S; Fisher LA; Wang L; Eurek NJ; Wahl JK; Lan L; Peng A Cancer Res; 2019 May; 79(10):2526-2535. PubMed ID: 30733193 [TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Henning RJ; Bourgeois M; Harbison RD Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072 [TBL] [Abstract][Full Text] [Related]
4. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo. Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402 [TBL] [Abstract][Full Text] [Related]
5. MORC2 regulates DNA damage response through a PARP1-dependent pathway. Zhang L; Li DQ Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951 [TBL] [Abstract][Full Text] [Related]
6. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells. Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646 [TBL] [Abstract][Full Text] [Related]
7. PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells. Huang M; Zhu X; Wang C; He L; Li L; Wang H; Fan G; Wang Y Cell Death Dis; 2024 Aug; 15(8):610. PubMed ID: 39174499 [TBL] [Abstract][Full Text] [Related]
8. PARP1-modulated chromatin remodeling is a new target for cancer treatment. Sinha S; Molla S; Kundu CN Med Oncol; 2021 Aug; 38(10):118. PubMed ID: 34432161 [TBL] [Abstract][Full Text] [Related]
9. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage. Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748 [TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanisms of regulaion of transcription by PARP1]. Maliuchenko NV; Kulaeva OI; Kotova E; Chupyrkina AA; Nikitin DV; Kirpichnikov MP; Studitskiĭ VM Mol Biol (Mosk); 2015; 49(1):99-113. PubMed ID: 25916114 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019 [TBL] [Abstract][Full Text] [Related]
12. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways. Ghosh R; Roy S; Kamyab J; Danzter F; Franco S DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144 [TBL] [Abstract][Full Text] [Related]
13. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. Jain PG; Patel BD Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797 [TBL] [Abstract][Full Text] [Related]
14. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825 [TBL] [Abstract][Full Text] [Related]
15. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Feng FY; de Bono JS; Rubin MA; Knudsen KE Mol Cell; 2015 Jun; 58(6):925-34. PubMed ID: 26091341 [TBL] [Abstract][Full Text] [Related]
16. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301 [TBL] [Abstract][Full Text] [Related]
17. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities. Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948 [TBL] [Abstract][Full Text] [Related]
18. Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region. Dallavalle S; Princiotto S; Mattio LM; Artali R; Musso L; Aviñó A; Eritja R; Pisano C; Gargallo R; Mazzini S Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445442 [TBL] [Abstract][Full Text] [Related]
19. The HSF1-PARP13-PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis. Fujimoto M; Takii R; Takaki E; Katiyar A; Nakato R; Shirahige K; Nakai A Nat Commun; 2017 Nov; 8(1):1638. PubMed ID: 29158484 [TBL] [Abstract][Full Text] [Related]
20. Nuclear PARP1-Targeted Photosensitizer as a Dual-Mode DNA-Damaging Agent and Immune Activator for Tumor Ablation. Li P; Du Y; Qiu J; Li D; Li G; Shan G Adv Healthc Mater; 2023 Dec; 12(31):e2301517. PubMed ID: 37689990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]